| __timestamp | Merck & Co., Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 11606000000 | 90480000 |
| Thursday, January 1, 2015 | 10313000000 | 133384000 |
| Friday, January 1, 2016 | 9762000000 | 179997000 |
| Sunday, January 1, 2017 | 9830000000 | 220119000 |
| Monday, January 1, 2018 | 10102000000 | 258528000 |
| Tuesday, January 1, 2019 | 10615000000 | 198205000 |
| Wednesday, January 1, 2020 | 8955000000 | 181022000 |
| Friday, January 1, 2021 | 9634000000 | 198359000 |
| Saturday, January 1, 2022 | 10042000000 | 208789000 |
| Sunday, January 1, 2023 | 10504000000 | 211124000 |
Data in motion
In the world of pharmaceuticals and biotechnology, understanding financial trends is crucial. This chart offers a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of two industry players: Merck & Co., Inc. and MiMedx Group, Inc., from 2014 to 2023.
Merck, a pharmaceutical giant, consistently reported SG&A expenses in the range of $9 billion to $11 billion annually. Notably, their expenses peaked in 2014 and saw a slight decline, only to rise again by 2023. This trend reflects Merck's strategic investments in marketing and administration, crucial for maintaining its market position.
In contrast, MiMedx, a smaller biotech firm, exhibited a different trajectory. Starting with expenses under $100 million in 2014, they experienced a steady increase, reaching over $200 million by 2023. This growth underscores MiMedx's expanding operations and market reach.
These insights reveal the dynamic nature of SG&A expenses and their impact on corporate strategy.
Merck & Co., Inc. or argenx SE: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Madrigal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Grifols, S.A.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and MiMedx Group, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and MiMedx Group, Inc.
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs MiMedx Group, Inc.
Catalyst Pharmaceuticals, Inc. or MiMedx Group, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.
BioCryst Pharmaceuticals, Inc. vs MiMedx Group, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Evotec SE or MiMedx Group, Inc.